Suchergebnisse - "Chau, Ian"

PubPharm (30)

1

LyRIC indeterminate response and Immune-mediated pseudoprogression of diffuse large B-cell lymphoma following polatuzumab-based salvage therapy

enthalten in: British journal of haematology | 2020

von Lee, A. | Attygale, A. | Sharma, R. | +10

CommentOn: J Clin Oncol. 2020 Jan 10;38(2):155-165. - PMID 31693429

2

Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution

enthalten in: Critical reviews in oncology/hematology | 2019

von Khan, K. | Valeri, N. | Dearman, C. | +5

3

Ramucirumab and its use in the treatment of hepatocellular carcinoma

enthalten in: Future oncology (London, England) | 2019

von Turkes, F. | Chau, I.

4

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer : Nonrandomized, Open-Label, Phase I Trial (JVDF)

enthalten in: The oncologist | 2018

von Arkenau, H. | Martin-Liberal, J. | Calvo, E. | +9

5

Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo : an analysis of the phase 3 REACH study

enthalten in: British journal of cancer | 2018

von Chau, I. | Park, J. | Ryoo, B. | +17

6

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy : American Society of Clinical Oncology Clinical Practice Guideline

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2018

von Brahmer, J. | Lacchetti, C. | Schneider, B. | +27

CommentIn: Strahlenther Onkol. 2019 Apr;195(4):365-366. - PMID 30770936

7

Age does not influence efficacy of ramucirumab in advanced gastric cancer : Subgroup analyses of REGARD and RAINBOW

enthalten in: Journal of gastroenterology and hepatology | 2018

von Muro, K. | Cho, J. | Bodoky, G. | +15

8

Checkpoint inhibition : an ATTRACTION in advanced gastric cancer?

enthalten in: Lancet (London, England) | 2017

von Chau, I.

9

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib : Patient-focused outcome results from the randomised phase III REACH study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2017

von Chau, I. | Peck-Radosavljevic, M. | Borg, C. | +18

ErratumIn: Eur J Cancer. 2018 Sep;100:135-136. - PMID 29970352

10

Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab

enthalten in: British journal of cancer | 2016

von Fuchs, C. | Tabernero, J. | Tomášek, J. | +16